RUNX2/CBFB modulates the response to MEK inhibitors through activation of receptor tyrosine kinases in KRAS mutant colorectal cancer

ABSTRACT: Investigation of the transcriptional consequences of RUNX2 and CBFB loss in the presence and absence of the MEK inhibitor selumetinib in LoVo ERN1 knockout KRAS mutant colorectal cancer cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE139169 | GEO | 2019/10/22

REPOSITORIES: GEO